Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
S1211
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- NCT01668719 ↗
- Completed
- SWOG Cancer Research Network
- Standard
We haven't built an HCP commentary report on S1211 (elotuzumab, bortezomib and 2 more in DS Stage I Plasma Cell Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S1211 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 6 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma
- Interventions
- Bortezomib; Dexamethasone; Elotuzumab; Laboratory Biomarker Analysis; Lenalidomide
- Arms
- Arm I (bortezomib, lenalidomide, dexamethasone) · Active comparator
- Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab) · Experimental
- Enrollment
- 142
- Primary outcomes
- Phase I: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Bortezomib, Lenalidomide and Dexamethasone
- Progression-free Survival
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Nov 2012
- Primary completion
- Feb 5, 2020
- Results posted
- Yes
- Registry record
- NCT01668719 · updated Apr 28, 2026
Publications
linked from the registry- Banerjee R, Sexton R, Cowan AJ, Rosenberg AS, Ailawadhi S, Rajkumar SV, Kumar S, Dispenzieri A, Lonial S, Durie BGM, Richardson PG, Usmani SZ, Hoering A, Orlowski RZ. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 Jan 2;145(1):75-84. doi: 10.1182/blood.2024025939. PubMed 39321347
- Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. PubMed 33357482